HC Wainwright & Co. Initiates Coverage On Regenxbio with Buy Rating, Announces Price Target of $36
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and a price target of $36.

March 11, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regenxbio receives a Buy rating from HC Wainwright & Co. with a price target of $36, indicating a positive outlook.
The initiation of coverage by HC Wainwright & Co. with a Buy rating and a price target significantly higher than the current trading price suggests a strong positive sentiment towards Regenxbio's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100